Mepolizumab decreases tissue eosinophils while increasing type-2 cytokines in eosinophilic chronic rhinosinusitis.
Sophie WalterJacqueline HoRaquel AlvaradoGreg SmithDavid R CroucherSharron LiangJessica W GraysonJoão Mangussi-GomesSimone L Van EsPeter EarlsJanet RimmerRaewyn CampbellLarry KalishRaymond SacksRichard J HarveyPublished in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2022)
Mepolizumab reduced eosinophils in sinonasal tissue, demonstrating that antagonism of IL-5 suppresses eosinophil trafficking. With reduced tissue eosinophils, a local type-2 inflammatory feedback loop may occur. The study exposes mechanistic factors which may explain incomplete treatment response.